参考文献
关键文献
National Institute for Health and Care Excellence. Psychosis and schizophrenia in adults: prevention and management. March 2014 [internet publication].全文
Scottish Intercollegiate Guidelines Network. Management of schizophrenia: a national clinical guideline. March 2013 [internet publication].全文
Barnes TR, Drake R, Paton C, et al. Evidence-based guidelines for the pharmacological treatment of schizophrenia: updated recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2020 Jan;34(1):3-78.全文 摘要
Taylor DM, Barnes TRE, Young AH. The Maudsley prescribing guidelines in psychiatry. 13th edition. Chichester: Wiley-Blackwell; 2018.
Howes OD, McCutcheon R, Agid O, et al. Treatment-resistant schizophrenia: treatment response and resistance in psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology. Am J Psychiatry. 2017 Mar 1;174(3):216-29.全文 摘要
参考文献
1. National Institute for Health and Care Excellence. Psychosis and schizophrenia in adults: prevention and management. March 2014 [internet publication].全文
2. Scottish Intercollegiate Guidelines Network. Management of schizophrenia: a national clinical guideline. March 2013 [internet publication].全文
3. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Washington, DC: American Psychiatric Press; 2013.
4. World Health Organization. International statistical classification of diseases and related health problems (ICD): ICD-11. September 2020 [internet publication].全文
5. National Collaborating Centre for Mental Health. Psychosis and schizophrenia in adults: the NICE guideline on treatment and management. 2014 [internet publication].全文
6. Reed GM, First MB, Kogan CS, et al. Innovations and changes in the ICD-11 classification of mental, behavioural and neurodevelopmental disorders. World Psychiatry. 2019 Feb;18(1):3-19.全文 摘要
7. McGrath J, Saha S, Chant D, et al. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev. 2008;30:67-76.全文 摘要
8. McGrath JJ. Myths and plain truths about schizophrenia epidemiology - the NAPE lecture 2004. Acta Psychiatr Scand. 2005 Jan;111(1):4-11. 摘要
9. Jablensky A, Sartorius N, Ernberg G, et al. Schizophrenia: manifestations, incidence and course in different cultures. A World Health Organization ten-country study. Psychol Med Monogr Suppl. 1992;20:1-97. 摘要
10. Gupta S, Murray RM. The relationship of environmental temperature to the incidence and outcome of schizophrenia. Br J Psychiatry. 1992 Jun;160:788-92. 摘要
11. Piotrowski P, Gondek TM, Królicka-Deręgowska A, et al. Causes of mortality in schizophrenia: an updated review of European studies. Psychiatr Danub. 2017 Jun;29(2):108-20. 摘要
12. Mitchell AJ, Malone D. Physical health and schizophrenia. Curr Opin Psychiatry. 2006 Jul;19(4):432-7. 摘要
13. Fazel S, Wolf A, Palm C, et al. Violent crime, suicide, and premature mortality in patients with schizophrenia and related disorders: a 38-year total population study in Sweden. Lancet Psychiatry. 2014 Jun;1(1):44-54.全文 摘要
14. Torrey EF, Miller J, Rawlings R, et al. Seasonal birth patterns of neurological disorders. Neuroepidemiology. 2000 Jul-Aug;19(4):177-85. 摘要
15. McGrath JJ, Welham JL. Season of birth and schizophrenia: a systematic review and meta-analysis of data from the Southern Hemisphere. Schizophr Res. 1999 Feb 15;35(3):237-42. 摘要
16. Bota RG, Munro JS, Sagduyu K. Identification of the schizophrenia prodrome in a hospital-based patient population. Mo Med. 2005 Mar-Apr;102(2):142-6. 摘要
17. Werbeloff N, Levine SZ, Rabinowitz J. Elaboration on the association between immigration and schizophrenia: a population-based national study disaggregating annual trends, country of origin and sex over 15 years. Soc Psychiatry Psychiatr Epidemiol. 2012 Feb;47(2):303-11. 摘要
18. Bourque F, van der Ven E, Malla A. A meta-analysis of the risk for psychotic disorders among first- and second-generation immigrants. Psychol Med. 2011 May;41(5):897-910. 摘要
19. National Institute for Health and Care Excellence. Psychosis and schizophrenia in children and young people: recognition and management. October 2016 [internet publication].全文
20. Walker EF, Diforio D. Schizophrenia: a neural diathesis-stress model. Psychol Rev. 1997 Oct;104(4):667-85. 摘要
21. Tsuang M. Schizophrenia: genes and environment. Biol Psychiatry. 2000 Feb 1;47(3):210-20. 摘要
22. Hough CJ, Ursano RJ. A guide to the genetics of psychiatric disease. Psychiatry. 2006 Spring;69(1):1-20. 摘要
23. Kuswanto CN, Teh I, Lee T-S, et al. Diffusion tensor imaging findings of white matter changes in first episode schizophrenia: a systematic review. Clin Psychopharmacol Neurosci. 2012 Apr;10(1):13-24.全文 摘要
24. Huber G. Prodromal symptoms in schizophrenia [in German]. Fortschr Neurol Psychiatr. 1995 Apr;63(4):131-8. 摘要
25. McCarley RW, Wible CG, Frumin M, et al. MRI anatomy of schizophrenia. Biol Psychiatry. 1999 May 1;45(9):1099-119.全文 摘要
26. Andreasen NC, Rezai K, Alliger R, et al. Hypofrontality in neuroleptic-naive patients and in patients with chronic schizophrenia. Assessment with xenon 133 single-photon emission computed tomography and the Tower of London. Arch Gen Psychiatry. 1992 Dec;49(12):943-58. 摘要
27. Keshavan MS, Reynolds CF, Miewald MJ, et al. Delta sleep deficits in schizophrenia: evidence from automated analyses of sleep data. Arch Gen Psychiatry. 1998 May;55(5):443-8.全文 摘要
28. Salisbury DF, Shenton ME, McCarley RW. P300 topography differs in schizophrenia and manic psychosis. Biol Psychiatry. 1999 Jan 1;45(1):98-106. 摘要
29. Light GA, Geyer MA, Clementz BA, et al. Normal P50 suppression in schizophrenia patients treated with atypical antipsychotic medications. Am J Psychiatry. 2000 May;157(5):767-71. 摘要
30. Sawa A, Snyder SH. Schizophrenia: diverse approaches to a complex disease. Science. 2002 Apr 26;296(5568):692-5. 摘要
31. Laruelle M. Imaging dopamine transmission in schizophrenia: a review and meta-analysis. Q J Nucl Med. 1998 Sep;42(3):211-21. 摘要
32. Laruelle M, Abi-Dargham A. Dopamine as the wind of the psychotic fire: new evidence from brain imaging studies. J Psychopharmacol. 1999 Dec;13(4):358-71. 摘要
33. Schobel SA, Chaudhury NH, Khan UA, et al. Imaging patients with psychosis and a mouse model establishes a spreading pattern of hippocampal dysfunction and implicates glutamate as a driver. Neuron. 2013 Apr 10;78(1):81-93.全文 摘要
34. Smith TE, Hull JW, Huppert JD, et al. Insight and recovery from psychosis in chronic schizophrenia and schizoaffective disorder patients. J Psychiatr Res. 2004 Mar-Apr;38(2):169-76. 摘要
35. Miller B, Messias E, Miettunen J, et al. Meta-analysis of paternal age and schizophrenia risk in male versus female offspring. Schizophr Bull. 2011 Sep;37(5):1039-47.全文 摘要
36. Clarke MC, Harley M, Cannon M. The role of obstetric events in schizophrenia. Schizophr Bull. 2006 Jan;32(1):3-8.全文 摘要
37. Macleod J, Davey Smith G, Hickman M. Does cannabis use cause schizophrenia? Lancet. 2006 Apr 1;367(9516):1055. 摘要
38. Arseneault L, Cannon M, Witton J, et al. Causal association between cannabis and psychosis: examination of the evidence. Br J Psychiatry. 2004 Feb;184:110-7. 摘要
39. Arendt M, Rosenberg R, Foldager L, et al. Cannabis-induced psychosis and subsequent schizophrenia-spectrum disorders: follow-up study of 535 incident cases. Br J Psychiatry. 2005 Dec;187:510-5. 摘要
40. Kuepper R, van Os J, Lieb R, et al. Continued cannabis use and risk of incidence and persistence of psychotic symptoms: 10 year follow-up cohort study. BMJ. 2011 Mar 1;342:d738.全文 摘要
41. McGrath J, Welham J, Scott J, et al. Association between cannabis use and psychosis-related outcomes using sibling pair analysis in a cohort of young adults. Arch Gen Psychiatry. 2010 May;67(5):440-7.全文 摘要
42. Hjorthøj C, Albert N, Nordentoft M. Association of substance use disorders with conversion from schizotypal disorder to schizophrenia. JAMA Psychiatry. 2018 Jul 1;75(7):733-9.全文 摘要
43. Schoeler T, Petros N, Di Forti M, et al. Poor medication adherence and risk of relapse associated with continued cannabis use in patients with first-episode psychosis: a prospective analysis. Lancet Psychiatry. 2017 Aug;4(8):627-33.全文 摘要
44. Ziermans T, de Wit S, Schothorst P, et al. Neurocognitive and clinical predictors of long-term outcome in adolescents at ultra-high risk for psychosis: a 6-year follow-up. PLoS One. 2014 Apr 4;9(4):e93994.全文 摘要
45. Mittal VA, Dean DJ, Bernard JA, et al. Neurological soft signs predict abnormal cerebellar-thalamic tract development and negative symptoms in adolescents at high risk for psychosis: a longitudinal perspective. Schizophr Bull. 2014 Nov;40(6):1204-15.全文 摘要
46. Dean DJ, Bernard JA, Orr JM, et al. Cerebellar morphology and procedural learning impairment in neuroleptic-naive youth at ultrahigh risk of psychosis. Clin Psychol Sci. 2014 Mar;2(2):152-64.全文 摘要
47. Bernard JA, Dean DJ, Kent JS, et al. Cerebellar networks in individuals at ultra high-risk of psychosis: impact on postural sway and symptom severity. Hum Brain Mapp. 2014 Aug;35(8):4064-78.全文 摘要
48. Corcoran C, Walker E, Huot R, et al. The stress cascade and schizophrenia: etiology and onset. Schizophr Bull. 2003;29(4):671-92. 摘要
49. Morgan C, Fisher H. Environment and schizophrenia: environmental factors in schizophrenia: childhood trauma - a critical review. Schizophr Bull. 2007 Jan;33(1):3-10.全文 摘要
50. Bradbury TN, Miller GA. Season of birth in schizophrenia: a review of evidence, methodology, and etiology. Psychol Bull. 1985 Nov;98(3):569-94. 摘要
51. Stafford MR, Jackson H, Mayo-Wilson E, et al. Early interventions to prevent psychosis: systematic review and meta-analysis. BMJ. 2013 Jan 18;346:f185.全文 摘要
52. National Institute for Health and Care Excellence. Violence and aggression: short-term management in mental health, health and community settings. May 2015 [internet publication].全文
53. Royal College of Psychiatrists. Psychiatry attachments. 2020 [internet publication].全文
54. Cole-King A, Platt S. Suicide prevention for physicians: identification, intervention and mitigation of risk. Medicine. 2017 Jan 27;45(3):131-4.
55. National Institute for Health and Care Excellence. Decision-making and mental capacity. October 2018 [internet publication].全文
56. Department for Constitutional Affairs. Mental Capacity Act 2005: Code of Practice. 2007 [internet publication].全文
57. National Institute for Health and Care Excellence. Patient experience in adult NHS services: improving the experience of care for people using adult NHS services. February 2012 [internet publication].
58. Soltan M, Girguis J. How to approach the mental state examination. BMJ. 2017 May 8;357:j1821. 摘要
59. Griswold KS, Del Regno PA, Berger RC. Recognition and differential diagnosis of psychosis in primary care. Am Fam Physician. 2015 Jun 15;91(12):856-63.全文 摘要
60. Barnes TR, Drake R, Paton C, et al. Evidence-based guidelines for the pharmacological treatment of schizophrenia: updated recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2020 Jan;34(1):3-78.全文 摘要
61. The National Archives. Mental Health Act 2007 [internet publication].全文
62. The National Archives. Mental Health (Scotland) Act 2015 [internet publication].全文
63. The National Archives. Mental Capacity Act (Northern Ireland) 2016 [internet publication].全文
64. Puntis S, Minichino A, De Crescenzo F, et al. Specialised early intervention teams for recent-onset psychosis. Cochrane Database Syst Rev. 2020 Nov 2;(11):CD013288.全文 摘要
65. Puntis S, Minichino A, De Crescenzo F, et al. Specialised early intervention teams (extended time) for recent-onset psychosis. Cochrane Database Syst Rev. 2020 Nov 2;(11):CD013287.全文 摘要
66. Rosen K, Garety P. Predicting recovery from schizophrenia: a retrospective comparison of characteristics at onset of people with single and multiple episodes. Schizophr Bull. 2005 Jul;31(3):735-50.全文 摘要
67. Jääskeläinen E, Juola P, Hirvonen N, et al. A systematic review and meta-analysis of recovery in schizophrenia. Schizophr Bull. 2013 Nov;39(6):1296-306.全文 摘要
68. Lally J, Ajnakina O, Stubbs B, et al. Remission and recovery from first-episode psychosis in adults: systematic review and meta-analysis of long-term outcome studies. Br J Psychiatry. 2017 Dec;211(6):350-8.全文 摘要
69. Santesteban-Echarri O, Paino M, Rice S, et al. Predictors of functional recovery in first-episode psychosis: a systematic review and meta-analysis of longitudinal studies. Clin Psychol Rev. 2017 Dec;58:59-75. 摘要
70. Trovão N, Prata J, VonDoellinger O, et al. Peripheral biomarkers for first-episode psychosis-opportunities from the neuroinflammatory hypothesis of schizophrenia. Psychiatry Investig. 2019 Mar;16(3):177-84.全文 摘要
71. Soares-Weiser K, Maayan N, Bergman H, et al. First rank symptoms for schizophrenia. Cochrane Database Syst Rev. 2015 Jan 25;(1):CD010653.全文 摘要
72. Lewandowski KE, DePaola J, Camsari GB, et al. Tactile, olfactory, and gustatory hallucinations in psychotic disorders: a descriptive study. Ann Acad Med Singap. 2009 May;38(5):383-5.全文 摘要
73. Sass L, Parnas, J. Thought disorder, subjectivity, and the self. Schizophr Bull. 2017 May 1;43(3):497-502.全文
74. Carpenter WT Jr, Strauss JS, Muleh S. Are there pathognomonic symptoms in schizophrenia? An empiric investigation of Schneider's first-rank symptoms. Arch Gen Psychiatry. 1973 Jun;28(6):847-52. 摘要
75. Upthegrove R, Marwaha S, Birchwood M. Depression and schizophrenia: cause, consequence, or trans-diagnostic issue? Schizophr Bull. 2017 Mar 1;43(2):240-4.全文 摘要
76. Grillo L. A possible link between anxiety and schizophrenia and a possible role of anhedonia. Schizophr Res Treatment. 2018 Jan 17;2018:5917475.全文 摘要
77. Dondé C, Vignaud P, Poulet E, et al. Management of depression in patients with schizophrenia spectrum disorders: a critical review of international guidelines. Acta Psychiatr Scand. 2018 Oct;138(4):289-99. 摘要
78. Cole-King A, Green G, Gask L, et al. Suicide mitigation: a compassionate approach to suicide prevention. Adv Psychiatr Treat. 2013;19(4):276-83.全文
79. Hor K, Taylor M. Suicide and schizophrenia: a systematic review of rates and risk factors. J Psychopharmacol. 2010 Nov;24(4 suppl):81-90.全文 摘要
80. Public Health England. NHS RightCare toolkit: physical ill-health and CVD prevention in people with severe mental Illness. March 2019 [internet publication].全文
81. Nordentoft M, Madsen T, Fedyszyn I. Suicidal behavior and mortality in first-episode psychosis. J Nerv Ment Dis. 2015 May;203(5):387-92. 摘要
82. Ventriglio A, Gentile A, Bonfitto I, et al. Suicide in the early stage of schizophrenia. Front Psychiatry. 2016 Jun 27;7:116.全文 摘要
83. Morrison P, Taylor DM, McGuire P. The Maudsley guidelines on advanced prescribing in psychosis. Chichester: Wiley-Blackwell; 2019.
84. Beattie N, Shannon C, Kavanagh M, et al. Predictors of PTSD symptoms in response to psychosis and psychiatric admission. J Nerv Ment Dis. 2009 Jan;197(1):56-60. 摘要
85. Mortensen PB, Pedersen MG, Pedersen CB. Psychiatric family history and schizophrenia risk in Denmark: which mental disorders are relevant? Psychol Med. 2010 Feb;40(2):201-10. 摘要
86. Schultz SH, North SW, Shields CG. Schizophrenia: a review. Am Fam Physician. 2007 Jun 15;75(12):1821-9.全文 摘要
87. Eaton WW, Mortensen PB, Frydenberg M. Obstetric factors, urbanization and psychosis. Schizophr Res. 2000 Jun 16;43(2-3):117-23. 摘要
88. Hollander AC, Dal H, Lewis G, et al. Refugee migration and risk of schizophrenia and other non-affective psychoses: cohort study of 1.3 million people in Sweden. BMJ. 2016 Mar 15;352:i1030.全文 摘要
89. Dalman C, Allebeck P, Cullberg J, et al. Obstetric complications and the risk of schizophrenia: a longitudinal study of a national birth cohort. Arch Gen Psychiatry. 1999 Mar;56(3):234-40.全文 摘要
90. Sørensen HJ, Mortensen EL, Schiffman J, et al. Early developmental milestones and risk of schizophrenia: a 45-year follow-up of the Copenhagen Perinatal Cohort. Schizophr Res. 2010 May;118(1-3):41-7.全文 摘要
91. Amminger GP, Pape S, Rock D, et al. Relationship between childhood behavioral disturbance and later schizophrenia in the New York high-risk project. Am J Psychiatry. 1999 Apr;156(4):525-30.全文 摘要
92. Morgese MG, Trabace L. Maternal malnutrition in the etiopathogenesis of psychiatric diseases: role of polyunsaturated fatty acids. Brain Sci. 2016 Jul 27;6(3):24.全文 摘要
93. Brown AS, Patterson PH. Maternal infection and schizophrenia: implications for prevention. Schizophr Bull. 2011 Mar;37(2):284-90.全文 摘要
94. Adorjan K, Papiol S, Gade K, et al. Polygenic risk burden and cannabis use comorbidity in patients with schizophrenia and bipolar disorder. Euro Neuropsych. 2019;29 (Suppl 3):S951.
95. Thoma P, Daum I. Comorbid substance use disorder in schizophrenia: a selective overview of neurobiological and cognitive underpinnings. Psychiatry Clin Neurosci. 2013 Sep;67(6):367-83. 摘要
96. Bradizza CM, Stasiewicz PR. Integrating substance abuse treatment for the seriously mentally ill into inpatient psychiatric treatment. J Subst Abuse Treat. 1997 Mar-Apr;14(2):103-11. 摘要
97. Ebel H, Schlegel U, Klosterkötter J. Chronic schizophreniform psychosis in primary hyperparathyroidism [in German]. Nervenarzt. 1992 Mar;63(3):180-3. 摘要
98. Engelhardt. Psychosis in primary hyperparathyroidism [in German]. Internist (Berl). 1991 Dec;32(12):738. 摘要
99. Joborn C, Hetta J, Palmér M, et al. Psychiatric symptomatology in patients with primary hyperparathyroidism. Ups J Med Sci. 1986;91(1):77-87. 摘要
100. Taylor DM, Gaughran F, Pillinger T. The Maudsley practice guidelines for physical health conditions in psychiatry. Chichester: Wiley-Blackwell; 2020.
101. Dalmau J, Lancaster E, Martinez-Hernandez E, et al. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol. 2011 Jan;10(1):63-74.全文 摘要
102. Ramanathan S, Al-Diwani A, Waters P, et al. The autoantibody-mediated encephalitides: from clinical observations to molecular pathogenesis. J Neurol. 2019 Oct 26 [Epub ahead of print].全文 摘要
103. Delangle R, Demeret S, Canlorbe G, et al. Anti-NMDA receptor encephalitis associated with ovarian tumor: the gynecologist point of view. Arch Gynecol Obstet. 2020 Aug;302(2):315-20. 摘要
104. Irani SR, Bera K, Waters P, et al. N-methyl-D-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes. Brain. 2010 Jun;133 (Pt 6):1655-67.全文 摘要
105. Lai M, Huijbers MG, Lancaster E, et al. Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series. Lancet Neurol. 2010 Aug;9(8):776-85.全文 摘要
106. Wang M, Cao X, Liu Q, et al. Clinical features of limbic encephalitis with LGI1 antibody. Neuropsychiatr Dis Treat. 2017 Jun 16;13:1589-96.全文 摘要
107. Li W, Wu S, Meng Q, et al. Clinical characteristics and short-term prognosis of LGI1 antibody encephalitis: a retrospective case study. BMC Neurol. 2018 Jul 6;18(1):96.全文 摘要
108. Thompson J, Bi M, Murchison AG, et al. The importance of early immunotherapy in patients with faciobrachial dystonic seizures. Brain. 2018 Feb 1;141(2):348-56.全文 摘要
109. Royal College of Emergency Medicine. The patient who absconds. June 2018 [internet publication].全文
110. Betz ME, Boudreaux ED. Managing suicidal patients in the emergency department. Ann Emerg Med. 2016 Feb;67(2):276-82.全文 摘要
111. Taylor DM, Barnes TRE, Young AH. The Maudsley prescribing guidelines in psychiatry. 13th edition. Chichester: Wiley-Blackwell; 2018.
112. Royal College of Psychiatrists. Consensus statement on high-dose antipsychotic medication. November 2014 [internet publication].全文
113. Cooper SJ, Reynolds GP, Barnes T, et al. BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment. J Psychopharmacol. 2016 Aug;30(8):717-48.全文 摘要
114. Howes OD, McCutcheon R, Agid O, et al. Treatment-resistant schizophrenia: treatment response and resistance in psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology. Am J Psychiatry. 2017 Mar 1;174(3):216-29.全文 摘要
116. Firth J, Siddiqi N, Koyanagi A, et al. The Lancet Psychiatry Commission: a blueprint for protecting physical health in people with mental illness. Lancet Psychiatry. 2019 Aug;6(8):675-712. 摘要
117. Jones C, Hacker D, Xia J, et al. Cognitive behavioural therapy plus standard care versus standard care for people with schizophrenia. Cochrane Database Syst Rev. 2018 Dec 20;(12):CD007964.全文 摘要
118. British National Formulary 77. Clozapine. London: BMJ Group, RCPCH Publications Ltd and the Royal Pharmaceutical Society of Great Britain. 2020.全文
119. Pollak TA, Lennox BR, Müller S, et al. Autoimmune psychosis: an international consensus on an approach to the diagnosis and management of psychosis of suspected autoimmune origin. Lancet Psychiatry. 2020 Jan;7(1):93-108. 摘要
120. Hynes C, Keating D, McWilliams S, et al. Glasgow antipsychotic side-effects scale for clozapine: development and validation of a clozapine-specific side-effects scale. Schizophr Res. 2015 Oct;168(1-2):505-13. 摘要
121. Velligan DI, Sajatovic M, Hatch A, et al. Why do psychiatric patients stop antipsychotic medication? A systematic review of reasons for nonadherence to medication in patients with serious mental illness. Patient Prefer Adherence. 2017;11:449-68.全文 摘要
122. Busner J, Targum SD. The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry (Edgmont). 2007 Jul;4(7):28-37. 摘要
123. Walter F, Carr MJ, Mok PLH, et al. Multiple adverse outcomes following first discharge from inpatient psychiatric care: a national cohort study. Lancet Psychiatry. 2019 Jul;6(7):582-9.全文 摘要
124. Gilbody S, Peckham E, Bailey D, et al. Smoking cessation for people with severe mental illness (SCIMITAR+): a pragmatic randomised controlled trial. Lancet Psychiatry. 2019 May;6(5):379-90.全文 摘要
125. Lean M, Fornells-Ambrojo M, Milton A, et al. Self-management interventions for people with severe mental illness: systematic review and meta-analysis. Br J Psychiatry. 2019 May;214(5):260-8.全文 摘要
126. Semple D, Smyth R. Oxford handbook of psychiatry. 3rd ed. Oxford: Oxford University Press; 2013.
127. Alphs L, Nasrallah HA, Bossie CA, et al. Factors associated with relapse in schizophrenia despite adherence to long-acting injectable antipsychotic therapy. Int Clin Psychopharmacol. 2016 Jul;31(4):202-9.全文 摘要
128. Colizzi M, Carra E, Fraietta S, et al. Substance use, medication adherence and outcome one year following a first episode of psychosis. Schizophr Res. 2016 Feb;170(2-3):311-7. 摘要
129. Tsuda Y, Saruwatari J, Yasui-Furukori N. Meta-analysis: the effects of smoking on the disposition of two commonly used antipsychotic agents, olanzapine and clozapine. BMJ Open. 2014 Mar 4;4(3):e004216.全文 摘要
130. Medicines and Healthcare products Regulatory Agency. Clozapine: reminder of potentially fatal risk of intestinal obstruction, faecal impaction, and paralytic ileus. October 2017 [internet publication].全文
131. National Institute for Health and Care Excellence. Guidance on the use of electroconvulsive therapy. October 2009 [internet publication].全文
132. Tharyan P, Adams CE. Electroconvulsive therapy for schizophrenia. Cochrane Database Syst Rev. 2005 Apr 18;(2):CD000076.全文 摘要
133. Chanpattana W, Chakrabhand ML, Sackeim HA, et al. Continuation ECT in treatment-resistant schizophrenia: a controlled study. J ECT. 1999 Sep;15(3):178-92. 摘要
134. Sinclair DJ, Zhao S, Qi F, et al. Electroconvulsive therapy for treatment-resistant schizophrenia. Cochrane Database Syst Rev. 2019 Mar 19;(3):CD011847.全文 摘要
135. Zheng W, Cai DB, Yang XH, et al. Adjunctive celecoxib for schizophrenia: a meta-analysis of randomized, double-blind, placebo-controlled trials. J Psychiatr Res. 2017 Sep;92:139-46. 摘要
136. Sommer IE, de Witte L, Begemann M, et al. Nonsteroidal anti-inflammatory drugs in schizophrenia: ready for practice or a good start? A meta-analysis. J Clin Psychiatry. 2012 Apr;73(4):414-9. 摘要
137. Kishi T, Matsuda Y, Nakamura H, et al. Blonanserin for schizophrenia: systematic review and meta-analysis of double-blind, randomized, controlled trials. J Psychiatr Res. 2013 Feb;47(2):149-54. 摘要
138. Lane HY, Lin CH, Green MF, et al. Add-on treatment of benzoate for schizophrenia: a randomized, double-blind, placebo-controlled trial of D-amino acid oxidase inhibitor. JAMA Psychiatry. 2013 Dec;70(12):1267-75. 摘要
139. Kulkarni J, Gavrilidis E, Gwini SM, et al. Effect of adjunctive raloxifene therapy on severity of refractory schizophrenia in women: a randomized clinical trial. JAMA Psychiatry. 2016 Sep 1;73(9):947-54. 摘要
140. Yu H, Yan H, Wang L, et al. Five novel loci associated with antipsychotic treatment response in patients with schizophrenia: a genome-wide association study. Lancet Psychiatry. 2018 Apr;5(4):327-38. 摘要
141. Ananth J, Parameswaran S, Hara B. Drug therapy in schizophrenia. Curr Pharm Des. 2004;10(18):2205-17. 摘要
142. Kern RS, Glynn SM, Horan WP, et al. Psychosocial treatments to promote functional recovery in schizophrenia. Schizophr Bull. 2009 Mar;35(2):347-61.全文 摘要
143. Horan WP, Kern RS, Shokat-Fadai K, et al. Social cognitive skills training in schizophrenia: an initial efficacy study of stabilized outpatients. Schizophr Res. 2009 Jan;107(1):47-54.全文 摘要
144. Kane JM, McGlashan TH. Treatment of schizophrenia. Lancet. 1995 Sep 23;346(8978):820-5. 摘要
145. Wyatt RJ. Neuroleptics and the natural course of schizophrenia. Schizophr Bull. 1991;17(2):325-51. 摘要
146. Larsen TK, McGlashan TH, Moe LC. First-episode schizophrenia: I. Early course parameters. Schizophr Bull. 1996;22(2):241-56. 摘要
147. Malla AK, Norman RM, Manchanda R, et al. Status of patients with first-episode psychosis after one year of phase-specific community-oriented treatment. Psychiatr Serv. 2002 Apr;53(4):458-63. 摘要
148. Norman RM, Malla AK. Duration of untreated psychosis: a critical examination of the concept and its importance. Psychol Med. 2001 Apr;31(3):381-400. 摘要
149. McGlashan TH. Duration of untreated psychosis in first-episode schizophrenia: marker or determinant of course? Biol Psychiatry. 1999 Oct 1;46(7):899-907. 摘要
150. Harrigan SM, McGorry PD, Krstev H. Does treatment delay in first-episode psychosis really matter? Psychol Med. 2003 Jan;33(1):97-110. 摘要
151. Craig TJ, Bromet EJ, Fennig S, et al. Is there an association between duration of untreated psychosis and 24-month clinical outcome in a first-admission series? Am J Psychiatry. 2000 Jan;157(1):60-6. 摘要
152. Robinson D, Woerner MG, Alvir JM, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry. 1999 Mar;56(3):241-7. 摘要
153. Marshall M, Rathbone J. Early intervention for psychosis. Cochrane Database Syst Rev. 2011 Jun 15;(6):CD004718.全文 摘要
154. Correll CU, Galling B, Pawar A, et al. Comparison of early intervention services vs treatment as usual for early-phase psychosis: a systematic review, meta-analysis, and meta-regression. JAMA Psychiatry. 2018 Jun 1;75(6):555-65.全文 摘要
155. Robinson DG, Woerner MG, Alvir JM, et al. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry. 1999 Apr;156(4):544-9. 摘要
156. Barnes TR, Soares-Weiser K, Bacaltchuk J, et al. Central action beta-blockers versus placebo for neuroleptic-induced acute akathisia. Cochrane Database Syst Rev. 2004 Oct 18;(4):CD001946.全文 摘要
157. Glassman AH. Schizophrenia, antipsychotic drugs, and cardiovascular disease. J Clin Psychiatry. 2005;66 suppl 6:5-10. 摘要
158. Gray R, Gournay K. What can we do about acute extrapyramidal symptoms? J Psychiatr Ment Health Nurs. 2000 Jun;7(3):205-11. 摘要
159. Velamoor VR, Swamy GN, Parmar RS, et al. Management of suspected neuroleptic malignant syndrome. Can J Psychiatry. 1995 Nov;40(9):545-50. 摘要
160. Klemp M, Tvete IF, Skomedal T, et al. A review and Bayesian meta-analysis of clinical efficacy and adverse effects of 4 atypical neuroleptic drugs compared with haloperidol and placebo. J Clin Psychopharmacol. 2011 Dec;31(6):698-704. 摘要
161. Hawton K, Sutton L, Haw C, et al. Schizophrenia and suicide: systematic review of risk factors. Br J Psychiatry. 2005 Jul;187:9-20. 摘要
162. Palmer BA, Pankratz VS, Bostwick JM. The lifetime risk of suicide in schizophrenia: a reexamination. Arch Gen Psychiatry. 2005 Mar;62(3):247-53.全文 摘要
163. Coyle JT. Substance use disorders and schizophrenia: a question of shared glutamatergic mechanisms. Neurotox Res. 2006 Dec;10(3-4):221-33. 摘要
164. Tsoi DT, Porwal M, Webster AC. Interventions for smoking cessation and reduction in individuals with schizophrenia. Cochrane Database Syst Rev. 2013 Feb 28;(2):CD007253.全文 摘要
165. Munetz MR, Benjamin S. How to examine patients using the Abnormal Involuntary Movement Scale. Hosp Community Psychiatry. 1988 Nov;39(11):1172-7. 摘要
166. Cubo E, Gracies JM, Benabou R, et al. Early morning off-medication dyskinesias, dystonia, and choreic subtypes. Arch Neurol. 2001 Sep;58(9):1379-82.全文 摘要
167. Buchanan RW, Panagides J, Zhao J, et al. Asenapine versus olanzapine in people with persistent negative symptoms of schizophrenia. J Clin Psychopharmacol. 2012 Feb;32(1):36-45. 摘要
168. Stephenson CM, Pilowsky LS. Psychopharmacology of olanzapine: a review. Br J Psychiatry Suppl. 1999;(38):52-8. 摘要
169. Leucht S, Kissling W, Davis JM. Second-generation antipsychotics for schizophrenia: can we resolve the conflict? Psychol Med. 2009 Oct;39(10):1591-602. 摘要
170. Naber D, Lambert M. The CATIE and CUtLASS studies in schizophrenia: results and implications for clinicians. CNS Drugs. 2009 Aug;23(8):649-59. 摘要
171. Nasrallah H. A review of the effect of atypical antipsychotics on weight. Psychoneuroendocrinology. 2003 Jan;28 suppl 1:83-96. 摘要
172. Das C, Mendez G, Jagasia S, et al. Second-generation antipsychotic use in schizophrenia and associated weight gain: a critical review and meta-analysis of behavioral and pharmacologic treatments. Ann Clin Psychiatry. 2012 Aug;24(3):225-39. 摘要
173. Mahmood S, Booker I, Huang J, et al. Effect of topiramate on weight gain in patients receiving atypical antipsychotic agents. J Clin Psychopharmacol. 2013 Feb;33(1):90-4. 摘要
174. Zhang Y, Dai G. Efficacy and metabolic influence of paliperidone ER, aripiprazole and ziprasidone to patients with first-episode schizophrenia through 52 weeks follow-up in China. Hum Psychopharmacol. 2012 Nov;27(6):605-14. 摘要
175. Mukundan A, Faulkner G, Cohn T, et al. Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems. Cochrane Database Syst Rev. 2010 Dec 8;(12):CD006629.全文 摘要
176. Jin H, Meyer JM, Jeste DV. Atypical antipsychotics and glucose dysregulation: a systematic review. Schizophr Res. 2004 Dec 1;71(2-3):195-212. 摘要
177. Newcomer JW. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J Clin Psychiatry. 2007;68 (Suppl 1):20-7. 摘要
178. Halbreich U, Kahn LS. Hyperprolactinemia and schizophrenia: mechanisms and clinical aspects. J Psychiatr Pract. 2003 Sep;9(5):344-53. 摘要
179. Nunes LV, Moreira HC, Razzouk D, et al. Strategies for the treatment of antipsychotic-induced sexual dysfunction and/or hyperprolactinemia among patients of the schizophrenia spectrum: a review. J Sex Marital Ther. 2012;38(3):281-301. 摘要
180. Bacconi L, Gressier F. Efficacy and tolerance of PDE-5 in the treatment of erectile dysfunction in schizophrenic patients: a literature review [in French]. Encephale. 2017 Feb;43(1):55-61. 摘要
181. Glassman AH, Bigger JT, Jr. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry. 2001 Nov;158(11):1774-82.全文 摘要
182. Collaborative Working Group on Clinical Trial Evaluations. Adverse effects of the atypical antipsychotics. J Clin Psychiatry. 1998;59 (Suppl 12):17-22. 摘要
183. Hjorthøj C, Stürup AE, McGrath JJ, et al. Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis. Lancet Psychiatry. 2017 Apr;4(4):295-301. 摘要
184. Vermeulen J, van Rooijen G, Doedens P, et al. Antipsychotic medication and long-term mortality risk in patients with schizophrenia; a systematic review and meta-analysis. Psychol Med. 2017 Oct;47(13):2217-28. 摘要
185. Katschnig H. Rehabilitation in schizophrenia - guidelines for including psychosocial measures [in German]. Wien Med Wochenschr. 1998;148(11-12):273-80. 摘要
186. Farooq S, Johal RK, Ziff C, et al. Different communication strategies for disclosing a diagnosis of schizophrenia and related disorders. Cochrane Database Syst Rev. 2017 Oct 24;(10):CD011707.全文 摘要
Comorbidities Manager reference articles
187. Patel MX, Sethi FN, Barnes TR, et al. Joint BAP NAPICU evidence-based consensus guidelines for the clinical management of acute disturbance: de-escalation and rapid tranquillisation. J Psychopharmacol. 2018 Jun;32(6):601-40 摘要
188. Díaz-Gutiérrez MJ, Martínez-Cengotitabengoa M, Sáez de Adana E, et al. Relationship between the use of benzodiazepines and falls in older adults: a systematic review. Maturitas. 2017 Jul;101:17-22 摘要
189. Rochon PA, Vozoris N, Gill SS. The harms of benzodiazepines for patients with dementia. CMAJ. 2017 Apr 10;189(14):E517-8全文 摘要
190. Wijeyakuhan N, Gruber R, Rattray NA. The cascade of benzodiazepine prescribing for hospitalized geriatric patients. J Community Hosp Intern Med Perspect. 2020 Oct 29;10(6):542-5全文 摘要
191. Baldwin DS, Aitchison K, Bateson A, et al. Benzodiazepines: risks and benefits: a reconsideration. J Psychopharmacol. 2013 Nov;27(11):967-71 摘要
192. Taylor DM, Barnes TRE, Young AH. The Maudsley prescribing guidelines in psychiatry. 14th edition. Chichester: Wiley-Blackwell; 2021
193. Vozoris NT, Fischer HD, Wang X, et al. Benzodiazepine drug use and adverse respiratory outcomes among older adults with COPD. Eur Respir J. 2014 Aug;44(2):332-40全文 摘要
194. Medicines and Healthcare products Regulatory Agency. Benzodiazepines and opioids: reminder of risk of potentially fatal respiratory depression. March 2020 [internet publication]全文
195. National Institute for Health and Care Excellence. Violence and aggression: short-term management in mental health, health and community settings. May 2015 [internet publication]全文
196. Wang MT, Tsai CL, Lin CW, et al. Association between antipsychotic agents and risk of acute respiratory failure in patients with chronic obstructive pulmonary disease. JAMA Psychiatry. 2017 Mar 1;74(3):252-60全文 摘要
197. Vandael E, Vandenberk B, Vandenberghe J, et al. Risk factors for QTc-prolongation: systematic review of the evidence. Int J Clin Pharm. 2017 Feb;39(1):16-25 摘要
198. Neef D, Walling AD. Dementia with Lewy bodies: an emerging disease. Am Fam Physician. 2006 Apr 1;73(7):1223-9全文 摘要
199. Gugger JJ. Antipsychotic pharmacotherapy and orthostatic hypotension: identification and management. CNS Drugs. 2011 Aug;25(8):659-71 摘要
200. National Institute for Health and Care Excellence. Violent and aggressive behaviours in people with mental health problems: quality statement 4 – physical health after rapid tranquillisation. June 2017 [internet publication]全文
201. Public Health England. NHS RightCare toolkit: physical ill-health and CVD prevention in people with severe mental Illness. March 2019 [internet publication]全文
202. Cooper SJ, Reynolds GP, Barnes T, et al. BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment. J Psychopharmacol. 2016 Aug;30(8):717-48全文 摘要
203. Firth J, Siddiqi N, Koyanagi A, et al. The Lancet Psychiatry Commission: a blueprint for protecting physical health in people with mental illness. Lancet Psychiatry. 2019 Aug;6(8):675-712 摘要
204. World Health Organization. Schizophrenia. January 2022 [internet publication]全文
205. Joint British Diabetes Societies for Inpatient Care. The management of diabetes in adults and children with psychiatric disorders in inpatient settings. May 2017 [internet publication]全文
206. Pendlebury ST, Klaus SP, Mather M, et al. Routine cognitive screening in older patients admitted to acute medicine: abbreviated mental test score (AMTS) and subjective memory complaint versus Montreal Cognitive Assessment and IQCODE. Age Ageing. 2015 Oct 13;44(6):1000-5全文 摘要
207. Hodkinson HM. Evaluation of a mental test score for assessment of mental impairment in the elderly. Age Ageing. 1972 Nov;1(4):233-8 摘要
208. National Institute for Health and Care Excellence. Delirium: prevention, diagnosis and management in hospital and long-term care. Jan 2023 [internet publication].全文
209. National Institute for Health and Care Excellence. Dementia: assessment, management and support for people living with dementia and their carers. Jun 2018 [internet publication].全文
210. Scottish Intercollegiate Guidelines Network. Risk reduction and management of delirium. Mar 2019 [internet publication].全文
211. Nova Scotia Health Authority. This is not my Mom. 2012 [internet publication]全文
212. Inouye SK, Schlesinger MJ, Lydon TJ. Delirium: a symptom of how hospital care is failing older persons and a window to improve quality of hospital care. Am J Med. 1999 May;106(5):565-73 摘要
213. Bellelli G, Morandi A, Davis DH, et al. Validation of the 4AT, a new instrument for rapid delirium screening: a study in 234 hospitalised older people. Age Ageing. 2014 Mar 2;43(4):496-502全文 摘要
214. MacLullich AM, Shenkin SD, Goodacre S, et al. The 4 'A's test for detecting delirium in acute medical patients: a diagnostic accuracy study. Health Technol Assess. 2019 Aug;23(40):1-194全文 摘要
215. Grau AJ, Urbanek C, Palm F. Common infections and the risk of stroke. Nat Rev Neurol. 2010 Nov 9;6(12):681-94 摘要
216. Eigenbrodt ML, Rose KM, Couper DJ, et al. Orthostatic hypotension as a risk factor for stroke: the atherosclerosis risk in communities (ARIC) study, 1987-1996. Stroke. 2000 Oct;31(10):2307-13 摘要
217. Winstein CJ, Stein J, Arena R, et al. Guidelines for adult stroke rehabilitation and recovery: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2016 May 4;47(6):e98-e169全文 摘要
218. Hogervorst VM, Buurman BM, De Jonghe A, et al. Emergency department management of older people living with frailty: a guide for emergency practitioners. Emerg Med J. 2021 Sep;38(9):724-9 摘要
219. NHS England. Toolkit for general practice in supporting older people living with frailty. March 2017 [internet publication]全文
220. Rockwood K; British Geriatrics Society. Silver book II: frailty. February 2021 [internet publication]全文
221. Royal College of Physicians. Acute care toolkit 3. Acute care for older people living with frailty. December 2020 [internet publication]全文
222. Wallis SJ, Wall J, Biram RW, et al. Association of the clinical frailty scale with hospital outcomes. QJM. 2015 Dec;108(12):943-9全文 摘要
223. Conroy SP, Bardsley M, Smith P, et al. Comprehensive geriatric assessment for frail older people in acute hospitals: the HoW-CGA mixed-methods study. Health Services and Delivery Research. 2019 April:7(15)全文
224. Quinn TJ, Mooijaart SP, Gallacher K, et al. Acute care assessment of older adults living with frailty. BMJ. 2019 Jan 31;364:l13 摘要
225. Fritz Z, Slowther AM, Perkins GD. Resuscitation policy should focus on the patient, not the decision. BMJ. 2017 Feb 28;356:j813全文 摘要
226. The National Institute for Health and Care Excellence. Decision making and mental capacity. October 2018 [internet publication]全文
227. Office of the Public Guardian. Mental Capacity Act: making decisions. Jun 2023 [internet publication]全文
228. Social Care Institute for Excellence. Independent mental capacity advocate (IMCA). January 2010 [internet publication]全文
229. Joint British Diabetes Societies for Inpatient Care. The management of diabetic ketoacidosis in adults. Mar 2023 [internet publication].全文
230. Joint British Diabetes Societies for Inpatient Care. The management of the hyperosmolar hyperglycaemic state (HHS) in adults. Feb 2022 [internet publication].全文
231. Chowdhury TA, Cheston H, Claydon A. Managing adults with diabetes in hospital during an acute illness. BMJ. 2017 Jun 22;357:j2551 摘要
232. Joint British Diabetes Societies for Inpatient Care. Self-management of diabetes in hospital. Feb 2023 [internet publication].全文
233. Joint British Diabetes Societies for Inpatient Care. Glycaemic management during the inpatient enteral feeding of stroke patients with diabetes. Nov 2019 [internet publication].全文
234. Joint British Diabetes Societies for Inpatient Care. The use of variable rate intravenous insulin infusion (VRIII) in medical inpatients. Oct 2014 [internet publication].全文
235. Joint British Diabetes Societies for Inpatient Care. A good inpatient diabetes service. Jul 2019 [internet publication].全文
236. Centre for Perioperative Care. Guideline for perioperative care for people with diabetes mellitus undergoing elective and emergency surgery. Dec 2022 [internet publication].全文
237. Pasquel FJ, Lansang MC, Dhatariya K, et al. Management of diabetes and hyperglycaemia in the hospital. Lancet Diabetes Endocrinol. 2021 Mar;9(3):174-88全文 摘要
238. Medicines and Healthcare products Regulatory Agency. SGLT2 inhibitors: monitor ketones in blood during treatment interruption for surgical procedures or acute serious medical illness. March 2020 [internet publication]全文
239. Peters AL, Buschur EO, Buse JB, et al. Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care. 2015 Jun 15;38(9):1687-93 摘要
240. ElSayed NA, Aleppo G, Aroda VR, et al, on behalf of the American Diabetes Association. 16. Diabetes care in the hospital: standards of care in diabetes - 2023. Diabetes Care. 2023 Jan 1;46(suppl 1):S267-78.全文 摘要
241. Joint British Diabetes Societies for Inpatient Care. A good inpatient diabetes service. Jul 2019 [internet publication].全文
242. National Institute for Health and Care Excellence. Type 1 diabetes in adults: diagnosis and management. Aug 2022 [internet publication].全文
243. Joint British Diabetes Societies for Inpatient Care. Inpatient care of the frail older adult with diabetes. Feb 2023 [internet publication].全文
244. van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in critically ill patients. N Engl J Med. 2001 Nov 8;345(19):1359-67全文 摘要
245. NICE-SUGAR Study Investigators, Finfer S, Chittock DR, et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med. 2009 Mar 26;360(13):1283-97.全文 摘要
246. Marik PE, Preiser JC. Toward understanding tight glycemic control in the ICU: a systematic review and metaanalysis. Chest. 2010 Mar;137(3):544-51全文 摘要
247. Rehman A, Setter SM, Vue MH. Drug-induced glucose alterations part 2: drug-Induced hyperglycemia. Diabetes Spect. 2011 Nov;24(4):234-8全文
248. NHS Digital. National Diabetes Inpatient Audit (NaDIA) - 2019. Nov 2020 [internet publication]全文
249. Joint British Diabetes Societies for Inpatient Care. The hospital management of hypoglycaemia in adults with diabetes mellitus. Jan 2023 [internet publication].全文
250. TREND Diabetes. End of life guidance for diabetes care. November 2021 [internet publication]全文
251. National Institute for Health and Care Excellence. Diabetic foot problems: prevention and management. October 2019 [internet publication]全文
252. Rayman G, Vas PR, Baker N, et al. The Ipswich Touch Test: a simple and novel method to identify inpatients with diabetes at risk of foot ulceration. Diabetes Care. 2011 May 18;34(7):1517-8全文 摘要
253. National Institute for Health and Care Excellence. Acute kidney injury: prevention, detection and management. December 2019 [internet publication]全文
254. Hsu CY, Ordoñez JD, Chertow GM, et al. The risk of acute renal failure in patients with chronic kidney disease. Kidney Int. 2008 Apr 2;74(1):101-7全文 摘要
255. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. 2023 [internet publication]全文
256. Kenna HA, Poon AW, de los Angeles CP, et al. Psychiatric complications of treatment with corticosteroids: review with case report. Psychiatry Clin Neurosci. 2011 Oct;65(6):549-60全文 摘要
257. Judd LL, Schettler PJ, Brown ES, et al. Adverse consequences of glucocorticoid medication: psychological, cognitive, and behavioral effects. Am J Psychiatry. 2014 Oct;171(10):1045-51全文 摘要
258. Warrington TP, Bostwick JM. Psychiatric adverse effects of corticosteroids. Mayo Clin Proc. 2006 Oct;81(10):1361-7全文 摘要
259. Salpeter SR, Ormiston TM, Salpeter EE. Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis. Chest. 2004 Jun;125(6):2309-21全文 摘要
260. Au DH, Curtis JR, Every NR, et al. Association between inhaled beta-agonists and the risk of unstable angina and myocardial infarction. Chest. 2002 Mar;121(3):846-51全文 摘要
261. Walters JA, Tan DJ, White CJ, et al. Different durations of corticosteroid therapy for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2018 Mar 19;3:CD006897全文 摘要
262. National Institute for Health and Care Excellence. Chronic obstructive pulmonary disease in over 16s: diagnosis and management. July 2019 [internet publication]全文
263. Mitchell C, Zuraw N, Delaney B, et al. Primary care for people with severe mental illness and comorbid obstructive airways disease: a qualitative study of patient perspectives with integrated stakeholder feedback. BMJ Open. 2022 Mar 1;12(3):e057143全文 摘要
264. National Institute for Health and Care Research (NIHR). How to improve care for people with a severe mental illness and a lung condition [internet publication]全文
265. British Thoracic Society; Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma: a national clinical guideline. July 2019 [internet publication].全文
266. Global Initiative for Asthma. Global strategy for asthma management and prevention. 2022 [internet publication]全文
267. Cleare A, Pariante CM, Young AH, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2008 British Association for Psychopharmacology guidelines. J Psychopharmacol. 2015 May 12;29(5):459-525全文 摘要
268. National Institute for Health and Care Excellence. Depression in adults with a chronic physical health problem: recognition and management. October 2009 [internet publication]全文
269. Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005 Mar 17;352(11):1112-20 摘要
270. Buckley NA, Dawson AH, Isbister GK. Serotonin syndrome. BMJ. 2014 Feb 19;348:g1626 摘要
271. Dalton SO, Sørensen HT, Johansen C. SSRIs and upper gastrointestinal bleeding: what is known and how should it influence prescribing? CNS Drugs. 2006;20(2):143-51 摘要
272. Dalton SO, Johansen C, Mellemkjaer L, et al. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study. Arch Intern Med. 2003 Jan 13;163(1):59-64全文 摘要
273. Cheng YL, Hu HY, Lin XH, et al. Use of SSRI, but not SNRI, increased upper and lower gastrointestinal bleeding: a nationwide population-based cohort study in Taiwan. Medicine (Baltimore). 2015 Nov;94(46):e2022全文 摘要
274. Loke YK, Trivedi AN, Singh S. Meta-analysis: gastrointestinal bleeding due to interaction between selective serotonin uptake inhibitors and non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther. 2008 Jan 1;27(1):31-40全文 摘要
275. Flowers L. Nicotine replacement therapy. Am J Psychiatry Resid. 2016 Jun;11(6)4-7全文
276. Desai HD, Seabolt J, Jann MW. Smoking in patients receiving psychotropic medications: a pharmacokinetic perspective. CNS Drugs. 2001;15(6):469-94
277. Oliveira P, Ribeiro J, Donato H, Madeira N. Smoking and antidepressants pharmacokinetics: a systematic review. Ann Gen Psychiatry. 2017;16:17全文 摘要
278. National Centre for Smoking Cessation and Training. Smoking cessation and mental health: a briefing for front-line staff. 2014 [internet publication]全文
279. National Institute for Health and Care Excellence. Tobacco: preventing uptake, promoting quitting and treating dependence. Jan 2023 [internet publication].全文
280. Theodoulou A, Chepkin SC, Ye W, et al. Different doses, durations and modes of delivery of nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2023 Jun 19;6(6):CD013308全文 摘要
281. Rigotti NA, Kruse GR, Livingstone-Banks J, et al. Treatment of tobacco smoking: a review. JAMA. 2022 Feb 8;327(6):566-77.全文 摘要
282. Thomas KH, Dalili MN, López-López JA, et al. Comparative clinical effectiveness and safety of tobacco cessation pharmacotherapies and electronic cigarettes: a systematic review and network meta-analysis of randomized controlled trials. Addiction. 2022 Apr;117(4):861-76.全文 摘要
283. Livingstone-Banks J, Fanshawe TR, Thomas KH, et al. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev. 2023 June 28;6(6):CD006103全文
内容使用需遵循免责声明